BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 19502165)

  • 21. Early response to lamivudine therapy in clinically non-cirrhotic chronic hepatitis B patients with decompensation.
    Dai CY; Yu ML; Hsieh MY; Lee LP; Hou NJ; Huang JF; Chen SC; Lin ZY; Hsieh MY; Wang LY; Tsai JF; Chang WY; Chuang WL
    Liver Int; 2007 Dec; 27(10):1364-70. PubMed ID: 17900250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Entecavir for the long-term treatment of chronic hepatitis B.
    Gonzalez SA; Keeffe EB
    Expert Rev Anti Infect Ther; 2009 Nov; 7(9):1053-62. PubMed ID: 19883325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients.
    Cheng PN; Chang TT
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):569-79. PubMed ID: 18847396
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Discussion on the meaning of MELD score in the opportunity of the entecavir treatment of HBeAg-negative acute-on-chronic liver failure].
    Yan Y; Mai L; Zhu JY; Zhang Y; Ke WM
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Dec; 25(6):466-9. PubMed ID: 22734238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients?
    Sheldon J; Ramos B; Toro C; Ríos P; Martínez-Alarcón J; Bottecchia M; Romero M; Garcia-Samaniego J; Soriano V
    Antivir Ther; 2008; 13(1):97-102. PubMed ID: 18389903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Entecavir versus lamivudine in the treatment of chronic hepatitis B patients with hepatic decompensation.
    Hsu YC; Mo LR; Chang CY; Perng DS; Tseng CH; Lo GH; Tai CM; Lin CW; Hsu CC; Hsu CY; Huang SC; Lin JT
    Antivir Ther; 2012; 17(4):605-12. PubMed ID: 22301517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in liver histology as a "surrogate" end point of antiviral therapy for chronic HBV can predict progression to liver complications.
    Hui CK; Leung N; Shek WH; Zhang HY; Luk JM; Poon RT; Lo CM; Fan ST; Lau GK;
    J Clin Gastroenterol; 2008; 42(5):533-8. PubMed ID: 18344885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The short-term efficacy of antiviral treatment in patients with acute-on-chronic hepatitis B liver failure].
    Xu QH; Chen LB; Xu Z; Shu X; Chen N; Cao H; Zhang K; Li G
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Dec; 23(6):467-9. PubMed ID: 20718359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical relevance of HBV DNA load in patients with chronic hepatitis B infection.
    Madan K; Batra Y; Jha JK; Kumar S; Kalra N; Paul SB; Singh R; Duttagupta S; Panda SK; Acharya SK
    Trop Gastroenterol; 2008; 29(2):84-90. PubMed ID: 18972767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical value of Child-Turcotte-Pugh and model for end-stage liver disease score to predict the prognosis of chronic severe hepatitis].
    Jiang ZS; Jiang JN
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2007 Jul; 19(7):412-5. PubMed ID: 17631709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Profile, spectrum and significance of hepatitis B virus genotypes in chronic HBV-infected patients in Yunnan, China.
    You J; Sriplung H; Chongsuvivatwong V; Geater A; Zhuang L; Huang JH; Chen HY; Yu L; Tang BZ
    Hepatobiliary Pancreat Dis Int; 2008 Jun; 7(3):271-9. PubMed ID: 18522881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation.
    Chen CH; Lin CL; Hu TH; Hung CH; Tseng PL; Wang JH; Chang JY; Lu SN; Chien RN; Lee CM
    J Hepatol; 2014 Jun; 60(6):1127-34. PubMed ID: 24583247
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus-related decompensated cirrhosis.
    Hyun JJ; Seo YS; Yoon E; Kim TH; Kim DJ; Kang HS; Jung ES; Kim JH; An H; Kim JH; Yim HJ; Yeon JE; Lee HS; Byun KS; Um SH; Kim CD; Ryu HS
    Liver Int; 2012 Apr; 32(4):656-64. PubMed ID: 22099071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
    Yuen MF; Fung J; Seto WK; Wong DK; Yuen JC; Lai CL
    Antivir Ther; 2009; 14(5):679-85. PubMed ID: 19704171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic hepatitis B: who to treat and which choice of treatment?
    Di Marco V; Craxì A
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):281-91. PubMed ID: 19344242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term follow-up of liver transplanted HIV/hepatitis B virus coinfected patients: perfect control of hepatitis B virus replication and absence of mitochondrial toxicity.
    Tateo M; Roque-Afonso AM; Antonini TM; Medja F; Lombes A; Jardel C; Teicher E; Sebagh M; Roche B; Castaing D; Samuel D; Duclos-Vallee JC
    AIDS; 2009 Jun; 23(9):1069-76. PubMed ID: 19417577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antiviral effects of entecavir in patients with hepatitis B virus-related cirrhosis].
    Xu Y; Wang JB; Xu J; Jiao J; Zhang YG; Ji SW; Zhao P; Guo HH; Li Y; Zhou CY
    Zhonghua Gan Zang Bing Za Zhi; 2010 Feb; 18(2):109-12. PubMed ID: 20196949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical value of the model for end-stage liver disease score in predicting the prognosis of liver transplantation in patients with end-stage liver disease].
    Sun J; Guo ZH; Lai TS; Tang YQ; Su L; Huo F; Wang SP; Pu MS; Wen Q
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(9):1731-2, 1742. PubMed ID: 18819907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HD-03/ES: a promising herbal drug for HBV antiviral therapy.
    Kar P; Asim M; Sarma MP; Patki PS
    Antiviral Res; 2009 Dec; 84(3):249-53. PubMed ID: 19800917
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy.
    Shouval D; Lai CL; Chang TT; Cheinquer H; Martin P; Carosi G; Han S; Kaymakoglu S; Tamez R; Yang J; Tenney D; Brett-Smith H
    J Hepatol; 2009 Feb; 50(2):289-95. PubMed ID: 19070393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.